GHRP-6 Research Overview (also known as Growth Hormone Releasing Peptide-6, GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)

By , Founder of RUO Codes · Last updated

At a glance

GHRP-6 is a synthetic six-amino-acid peptide in the growth hormone-releasing peptide family. It activates the ghrelin receptor, linking growth hormone signaling with appetite-related pathways. Research discussed here examines hormonal responses, muscle growth, tissue repair and cardiovascular questions, with appetite and nutritional states forming part of the biological context.

What Is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the original member of the GHRP family of GH secretagogues. As a potent ghrelin receptor (GHSR-1a) agonist, it stimulates strong pulsatile GH release from the anterior pituitary. It has the most pronounced appetite-stimulating effect among the GHRPs — a consequence of its robust ghrelin receptor activation in hypothalamic feeding centers — which makes it particularly relevant for research in GH-deficient states and conditions of poor appetite or malnutrition.

Mechanism and Gastroprotective Effects

GHRP-6 agonizes ghrelin receptors on pituitary somatotrophs while reducing somatostatin tone. An important additional property is its gastroprotective activity: studies have shown GHRP-6 accelerates gastric ulcer healing, reduces intestinal inflammation, and protects against NSAID-induced gastric injury through ghrelin receptor activation in the GI tract.

Cardioprotective Research

GHRP-6 has demonstrated cardioprotective properties in ischemia-reperfusion injury models — reducing infarct size and improving cardiac function recovery through GHS-R1a receptors on cardiomyocytes and CD36-dependent anti-apoptotic signaling pathways. This cardioprotective property is shared with Hexarelin.

Quick Reference

Member reference tables summarize the compound's research parameters.

Sign in to view this section

Research Indications

Hormonal
Preliminary Data

Growth Hormone Release

Potent GH secretagogue with dose-dependent release demonstrated in human clinical studies via GHS-R1a activation

Synergy with GHRH Peptides

Simultaneous stimulation with GHRH-class peptides produces synergistic GH response 2-3x greater than either alone

IGF-1 Elevation

Sustained GH release increases downstream IGF-1 for anabolic and tissue repair support

Cardiovascular
Preliminary Data

Cardioprotection

In preclinical models, rescued >70% of ischemic myocardium in pigs. 100% survival in canine acute MI model vs 50% in controls. Human efficacy under investigation.

Doxorubicin Cardiotoxicity Prevention

Completely prevented cardiac dysfunction in doxorubicin-treated rats through prosurvival pathway activation (2024 preclinical study)

Anti-Fibrotic Cardiac Effects

Reduces cardiac fibrosis by increasing MMP-2/MMP-9 activities and decreasing TIMP-1 expression

Tissue Repair
Strong Evidence

Wound Healing

Topical GHRP-6 significantly accelerated wound closure and prevented hypertrophic scar formation in 90.5% of treated wounds

Neuroprotection

Combined with EGF, improved neurological outcomes and survival in Phase I/II acute ischemic stroke trial (2024)

Multi-Organ Cytoprotection

Pharmacological preconditioning reduces kidney, lung, and intestinal damage during ischemia/reperfusion injury

Muscle Growth
Preliminary Data

Lean Mass Support

GH and IGF-1 elevation supports muscle protein synthesis and body composition improvements over 8-12 week protocols

Recovery Enhancement

Pulsatile GH release supports exercise recovery, sleep quality, and tissue repair processes

Appetite Stimulation

Strong ghrelin-mediated appetite increase supports caloric surplus for muscle growth phases

Research Protocols

As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.

This member section describes parameters reported in the research literature.

Sign in to view this section

Peptide Interactions

This member section summarizes reported compound interactions and evidence limitations.

Sign in to view this section

Reported Research Time Points

This member section summarizes reported research time points.

Sign in to view this section

Safety Notes

Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.

This member section discusses research safety considerations and uncertainties.

Sign in to view this section

Quality Indicators

Verified Marker

White Lyophilized Powder

Pure GHRP-6 appears as white to off-white lyophilized powder or puck

Verified Marker

Clear Reconstituted Solution

Properly reconstituted solution should be crystal clear with no particles

Verified Marker

Certificate of Analysis

Should include HPLC purity (>98%), sequence confirmation, and endotoxin testing

Acceptable Range

Appetite Response Test

Noticeable hunger within 20 minutes of first injection indicates GHS-R1a activation and suggests active peptide. However, this is a basic indicator only—HPLC testing is still required to confirm purity and sequence integrity.

Quality Concern

Discolored or Cloudy Solution

Yellow or cloudy solution indicates degradation - do not use

Research Citations

Research Focus

Growth hormone release, Appetite stimulation, Muscle mass, Gastroprotection, Cardioprotection

Verified Vendors Carrying GHRP-6

Related Compounds

Related Articles

Browse all peptides in the Encyclopedia →